MARKET

ACRV

ACRV

Acrivon Therapeutics, Inc.
NASDAQ
2.100
-0.030
-1.41%
After Hours: 2.110 +0.01 +0.48% 19:48 09/08 EDT
OPEN
2.130
PREV CLOSE
2.130
HIGH
2.175
LOW
2.070
VOLUME
129.98K
TURNOVER
--
52 WEEK HIGH
3.560
52 WEEK LOW
1.270
MARKET CAP
89.99M
P/E (TTM)
-1.1141
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACRV last week (0831-0904)?
Weekly Report · 1d ago
Press Release: Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
Dow Jones · 08/31 12:30
Weekly Report: what happened at ACRV last week (0824-0828)?
Weekly Report · 08/31 10:10
Top Executive Makes Notable Move With Acrivon Therapeutics Stock
TipRanks · 08/28 02:04
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy
NASDAQ · 08/24 16:00
Weekly Report: what happened at ACRV last week (0817-0821)?
Weekly Report · 08/24 10:11
Weekly Report: what happened at ACRV last week (0810-0814)?
Weekly Report · 08/17 10:12
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Belite Bio, Inc. ADR (BLTE)
TipRanks · 08/14 16:50
More
About ACRV
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. It uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.

Webull offers Acrivon Therapeutics Inc stock information, including NASDAQ: ACRV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACRV stock methods without spending real money on the virtual paper trading platform.